Loading…

Evidence for DNA Damage Checkpoint Activation in Barrett Esophagus

Barrett esophagus is an epithelial metaplasia that predisposes to adenocarcinoma. Better markers of cancer risk are urgently needed to identify those patients who are likely to benefit most from emerging methods of endoscopic ablation. Disease progression is associated with genomic DNA changes (segm...

Full description

Saved in:
Bibliographic Details
Published in:Translational oncology 2010-02, Vol.3 (1), p.33-42
Main Authors: von Holzen, Urs, Chen, Tina, Boquoi, Amelie, Richter, Joel E., Falk, Gary W., Klein-Szanto, Andres J., Cooper, Harry, Litwin, Sam, Weinberg, David S., Enders, Greg H.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3337-a2c7fe0b1236a376d8417d9cd981c2ee032e61609dbffd69a9cb9e65539016583
cites cdi_FETCH-LOGICAL-c3337-a2c7fe0b1236a376d8417d9cd981c2ee032e61609dbffd69a9cb9e65539016583
container_end_page 42
container_issue 1
container_start_page 33
container_title Translational oncology
container_volume 3
creator von Holzen, Urs
Chen, Tina
Boquoi, Amelie
Richter, Joel E.
Falk, Gary W.
Klein-Szanto, Andres J.
Cooper, Harry
Litwin, Sam
Weinberg, David S.
Enders, Greg H.
description Barrett esophagus is an epithelial metaplasia that predisposes to adenocarcinoma. Better markers of cancer risk are urgently needed to identify those patients who are likely to benefit most from emerging methods of endoscopic ablation. Disease progression is associated with genomic DNA changes (segmental gains, losses, or loss of heterozygosity). Although these changes are not easily assayed directly, we hypothesized that the underlying DNA damage should activate a DNA damage response (DDR), detectable by immunohistochemical (IHC) assays of checkpoint proteins and the resulting replicative phase cell cycle delays. Surgical specimens and endoscopic biopsies (N = 28) were subjected to IHC for the cell cycle markers cyclin A and phosphorylated histone H3 (P-H3), the DDR markers γH2AX and phosphorylated ATM/ATR substrates (P-ATM/ATRsub), and the DNA damage-responsive tumor suppressors p16 and p53. Correlations were made with histologic diagnoses. The fractions of cells that stained for cyclin A, P-H3, and γH2AX increased in parallel in dysplastic tissue, consistent with checkpoint-mediated cell cycle delays. Foci of nuclear γH2AX and P-ATM/ATRsub were demonstrated by standard and confocal immunofluorescence. Staining for p16 was more prevalent in early-stage disease with lower staining for γH2AX and P-H3. Staining for p53 was moderately increased in some early-stage disease and strongly increased in some advanced disease, consistent with checkpoint-mediated induction and mutational inactivation of p53, respectively. We suggest that IHC for DDR-associated markers may help stratify risk of disease progression in Barrett.
doi_str_mv 10.1593/tlo.09187
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_734282464</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1936523310800415</els_id><sourcerecordid>734282464</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3337-a2c7fe0b1236a376d8417d9cd981c2ee032e61609dbffd69a9cb9e65539016583</originalsourceid><addsrcrecordid>eNptkMtKAzEUhoMotlYXvoDMTly05jKTmWyE3rxA0Y2uQ5qcaaPTSU3Sgm_v1NZSwdU5cD7-8_MhdElwj2SC3cbK9bAgRX6E2kQw3s0oY8cHewudhfCOMSeC0lPUopjwjAvWRoPx2hqoNSSl88nouZ-M1ELNIBnOQX8sna1j0tfRrlW0rk5snQyU9xBjMg5uOVezVThHJ6WqAlzsZge93Y9fh4_dycvD07A_6WrGWN5VVOcl4CmhjCuWc1OkJDdCG1EQTQEwo8AJx8JMy9JwoYSeCuBZxsSmbcE66G6bu1xNF2A01NGrSi69XSj_JZ2y8u-ltnM5c2tJC0rTRkMHXe8CvPtcQYhyYYOGqlI1uFWQOUsbNOVpQ95sSe1dCB7K_ReC5Ua5bJTLH-UNe3VYa0_-Om4AtgWgkbO24GXQdqPcWA86SuPsP7HfMzuODA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734282464</pqid></control><display><type>article</type><title>Evidence for DNA Damage Checkpoint Activation in Barrett Esophagus</title><source>ScienceDirect®</source><source>PMC (PubMed Central)</source><creator>von Holzen, Urs ; Chen, Tina ; Boquoi, Amelie ; Richter, Joel E. ; Falk, Gary W. ; Klein-Szanto, Andres J. ; Cooper, Harry ; Litwin, Sam ; Weinberg, David S. ; Enders, Greg H.</creator><creatorcontrib>von Holzen, Urs ; Chen, Tina ; Boquoi, Amelie ; Richter, Joel E. ; Falk, Gary W. ; Klein-Szanto, Andres J. ; Cooper, Harry ; Litwin, Sam ; Weinberg, David S. ; Enders, Greg H.</creatorcontrib><description>Barrett esophagus is an epithelial metaplasia that predisposes to adenocarcinoma. Better markers of cancer risk are urgently needed to identify those patients who are likely to benefit most from emerging methods of endoscopic ablation. Disease progression is associated with genomic DNA changes (segmental gains, losses, or loss of heterozygosity). Although these changes are not easily assayed directly, we hypothesized that the underlying DNA damage should activate a DNA damage response (DDR), detectable by immunohistochemical (IHC) assays of checkpoint proteins and the resulting replicative phase cell cycle delays. Surgical specimens and endoscopic biopsies (N = 28) were subjected to IHC for the cell cycle markers cyclin A and phosphorylated histone H3 (P-H3), the DDR markers γH2AX and phosphorylated ATM/ATR substrates (P-ATM/ATRsub), and the DNA damage-responsive tumor suppressors p16 and p53. Correlations were made with histologic diagnoses. The fractions of cells that stained for cyclin A, P-H3, and γH2AX increased in parallel in dysplastic tissue, consistent with checkpoint-mediated cell cycle delays. Foci of nuclear γH2AX and P-ATM/ATRsub were demonstrated by standard and confocal immunofluorescence. Staining for p16 was more prevalent in early-stage disease with lower staining for γH2AX and P-H3. Staining for p53 was moderately increased in some early-stage disease and strongly increased in some advanced disease, consistent with checkpoint-mediated induction and mutational inactivation of p53, respectively. We suggest that IHC for DDR-associated markers may help stratify risk of disease progression in Barrett.</description><identifier>ISSN: 1936-5233</identifier><identifier>EISSN: 1936-5233</identifier><identifier>DOI: 10.1593/tlo.09187</identifier><identifier>PMID: 20165693</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><ispartof>Translational oncology, 2010-02, Vol.3 (1), p.33-42</ispartof><rights>2012 Neoplasia Press, Inc.</rights><rights>Copyright © 2010 Neoplasia Press, Inc. All rights reserved</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3337-a2c7fe0b1236a376d8417d9cd981c2ee032e61609dbffd69a9cb9e65539016583</citedby><cites>FETCH-LOGICAL-c3337-a2c7fe0b1236a376d8417d9cd981c2ee032e61609dbffd69a9cb9e65539016583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822452/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1936523310800415$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3549,27924,27925,45780,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20165693$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>von Holzen, Urs</creatorcontrib><creatorcontrib>Chen, Tina</creatorcontrib><creatorcontrib>Boquoi, Amelie</creatorcontrib><creatorcontrib>Richter, Joel E.</creatorcontrib><creatorcontrib>Falk, Gary W.</creatorcontrib><creatorcontrib>Klein-Szanto, Andres J.</creatorcontrib><creatorcontrib>Cooper, Harry</creatorcontrib><creatorcontrib>Litwin, Sam</creatorcontrib><creatorcontrib>Weinberg, David S.</creatorcontrib><creatorcontrib>Enders, Greg H.</creatorcontrib><title>Evidence for DNA Damage Checkpoint Activation in Barrett Esophagus</title><title>Translational oncology</title><addtitle>Transl Oncol</addtitle><description>Barrett esophagus is an epithelial metaplasia that predisposes to adenocarcinoma. Better markers of cancer risk are urgently needed to identify those patients who are likely to benefit most from emerging methods of endoscopic ablation. Disease progression is associated with genomic DNA changes (segmental gains, losses, or loss of heterozygosity). Although these changes are not easily assayed directly, we hypothesized that the underlying DNA damage should activate a DNA damage response (DDR), detectable by immunohistochemical (IHC) assays of checkpoint proteins and the resulting replicative phase cell cycle delays. Surgical specimens and endoscopic biopsies (N = 28) were subjected to IHC for the cell cycle markers cyclin A and phosphorylated histone H3 (P-H3), the DDR markers γH2AX and phosphorylated ATM/ATR substrates (P-ATM/ATRsub), and the DNA damage-responsive tumor suppressors p16 and p53. Correlations were made with histologic diagnoses. The fractions of cells that stained for cyclin A, P-H3, and γH2AX increased in parallel in dysplastic tissue, consistent with checkpoint-mediated cell cycle delays. Foci of nuclear γH2AX and P-ATM/ATRsub were demonstrated by standard and confocal immunofluorescence. Staining for p16 was more prevalent in early-stage disease with lower staining for γH2AX and P-H3. Staining for p53 was moderately increased in some early-stage disease and strongly increased in some advanced disease, consistent with checkpoint-mediated induction and mutational inactivation of p53, respectively. We suggest that IHC for DDR-associated markers may help stratify risk of disease progression in Barrett.</description><issn>1936-5233</issn><issn>1936-5233</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNptkMtKAzEUhoMotlYXvoDMTly05jKTmWyE3rxA0Y2uQ5qcaaPTSU3Sgm_v1NZSwdU5cD7-8_MhdElwj2SC3cbK9bAgRX6E2kQw3s0oY8cHewudhfCOMSeC0lPUopjwjAvWRoPx2hqoNSSl88nouZ-M1ELNIBnOQX8sna1j0tfRrlW0rk5snQyU9xBjMg5uOVezVThHJ6WqAlzsZge93Y9fh4_dycvD07A_6WrGWN5VVOcl4CmhjCuWc1OkJDdCG1EQTQEwo8AJx8JMy9JwoYSeCuBZxsSmbcE66G6bu1xNF2A01NGrSi69XSj_JZ2y8u-ltnM5c2tJC0rTRkMHXe8CvPtcQYhyYYOGqlI1uFWQOUsbNOVpQ95sSe1dCB7K_ReC5Ua5bJTLH-UNe3VYa0_-Om4AtgWgkbO24GXQdqPcWA86SuPsP7HfMzuODA</recordid><startdate>20100201</startdate><enddate>20100201</enddate><creator>von Holzen, Urs</creator><creator>Chen, Tina</creator><creator>Boquoi, Amelie</creator><creator>Richter, Joel E.</creator><creator>Falk, Gary W.</creator><creator>Klein-Szanto, Andres J.</creator><creator>Cooper, Harry</creator><creator>Litwin, Sam</creator><creator>Weinberg, David S.</creator><creator>Enders, Greg H.</creator><general>Elsevier Inc</general><general>Neoplasia Press Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20100201</creationdate><title>Evidence for DNA Damage Checkpoint Activation in Barrett Esophagus</title><author>von Holzen, Urs ; Chen, Tina ; Boquoi, Amelie ; Richter, Joel E. ; Falk, Gary W. ; Klein-Szanto, Andres J. ; Cooper, Harry ; Litwin, Sam ; Weinberg, David S. ; Enders, Greg H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3337-a2c7fe0b1236a376d8417d9cd981c2ee032e61609dbffd69a9cb9e65539016583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>von Holzen, Urs</creatorcontrib><creatorcontrib>Chen, Tina</creatorcontrib><creatorcontrib>Boquoi, Amelie</creatorcontrib><creatorcontrib>Richter, Joel E.</creatorcontrib><creatorcontrib>Falk, Gary W.</creatorcontrib><creatorcontrib>Klein-Szanto, Andres J.</creatorcontrib><creatorcontrib>Cooper, Harry</creatorcontrib><creatorcontrib>Litwin, Sam</creatorcontrib><creatorcontrib>Weinberg, David S.</creatorcontrib><creatorcontrib>Enders, Greg H.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Translational oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>von Holzen, Urs</au><au>Chen, Tina</au><au>Boquoi, Amelie</au><au>Richter, Joel E.</au><au>Falk, Gary W.</au><au>Klein-Szanto, Andres J.</au><au>Cooper, Harry</au><au>Litwin, Sam</au><au>Weinberg, David S.</au><au>Enders, Greg H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evidence for DNA Damage Checkpoint Activation in Barrett Esophagus</atitle><jtitle>Translational oncology</jtitle><addtitle>Transl Oncol</addtitle><date>2010-02-01</date><risdate>2010</risdate><volume>3</volume><issue>1</issue><spage>33</spage><epage>42</epage><pages>33-42</pages><issn>1936-5233</issn><eissn>1936-5233</eissn><abstract>Barrett esophagus is an epithelial metaplasia that predisposes to adenocarcinoma. Better markers of cancer risk are urgently needed to identify those patients who are likely to benefit most from emerging methods of endoscopic ablation. Disease progression is associated with genomic DNA changes (segmental gains, losses, or loss of heterozygosity). Although these changes are not easily assayed directly, we hypothesized that the underlying DNA damage should activate a DNA damage response (DDR), detectable by immunohistochemical (IHC) assays of checkpoint proteins and the resulting replicative phase cell cycle delays. Surgical specimens and endoscopic biopsies (N = 28) were subjected to IHC for the cell cycle markers cyclin A and phosphorylated histone H3 (P-H3), the DDR markers γH2AX and phosphorylated ATM/ATR substrates (P-ATM/ATRsub), and the DNA damage-responsive tumor suppressors p16 and p53. Correlations were made with histologic diagnoses. The fractions of cells that stained for cyclin A, P-H3, and γH2AX increased in parallel in dysplastic tissue, consistent with checkpoint-mediated cell cycle delays. Foci of nuclear γH2AX and P-ATM/ATRsub were demonstrated by standard and confocal immunofluorescence. Staining for p16 was more prevalent in early-stage disease with lower staining for γH2AX and P-H3. Staining for p53 was moderately increased in some early-stage disease and strongly increased in some advanced disease, consistent with checkpoint-mediated induction and mutational inactivation of p53, respectively. We suggest that IHC for DDR-associated markers may help stratify risk of disease progression in Barrett.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>20165693</pmid><doi>10.1593/tlo.09187</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1936-5233
ispartof Translational oncology, 2010-02, Vol.3 (1), p.33-42
issn 1936-5233
1936-5233
language eng
recordid cdi_proquest_miscellaneous_734282464
source ScienceDirect®; PMC (PubMed Central)
title Evidence for DNA Damage Checkpoint Activation in Barrett Esophagus
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A37%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evidence%20for%20DNA%20Damage%20Checkpoint%20Activation%20in%20Barrett%20Esophagus&rft.jtitle=Translational%20oncology&rft.au=von%20Holzen,%20Urs&rft.date=2010-02-01&rft.volume=3&rft.issue=1&rft.spage=33&rft.epage=42&rft.pages=33-42&rft.issn=1936-5233&rft.eissn=1936-5233&rft_id=info:doi/10.1593/tlo.09187&rft_dat=%3Cproquest_pubme%3E734282464%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3337-a2c7fe0b1236a376d8417d9cd981c2ee032e61609dbffd69a9cb9e65539016583%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=734282464&rft_id=info:pmid/20165693&rfr_iscdi=true